Home › Compare › ERILF vs ABBV
ERILF yields 20000.00% · ABBV yields 3.12%● Live data
📍 ERILF pulled ahead of the other in Year 1
Combined, ERILF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ERILF + ABBV for your $10,000?
Dynamic Technologies Group Inc. designs, builds, and installs entertainment attractions and ride systems for the entertainment industry. The company operates through Ride Systems Manufacturing, and Parts and Service segments. It also applies turn-key integration services for special projects, such as alternative energy, large optical telescopes, and enclosures, as well as custom steel fabrication services. In addition, the company provides custom design-build-commission services for custom ride systems and attractions, as well as parts and services to park operators for its own ride systems and those ride systems supplied by others. Further, it owns and operates the SkyFlyTM Soar America flying theater attraction at the Island in Pigeon Forge theme park in Tennessee; provides design engineering and product research and development services for complex ride systems; and designs integrated structures, such as astronomical telescope enclosures for third party customers. The company serves theme parks, stand-alone tourist venues, and the government sector in Canada, the United States, Asia, the Middle East, and Europe. The company was formerly known as Empire Industries Ltd. and changed its name to Dynamic Technologies Group Inc. in March 2021. Dynamic Technologies Group Inc. was founded in 1926 and is headquartered in Toronto, Canada.
Full ERILF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.